PuREC secures $5.8 mil series B financing with Mochida Pharma, San-in Godo Bank and other parties.
PuREC, a clinical-stage biotech startup with unique MSC cell therapy “REC”, has raised JPY 7.0 billion ($5.8 million) with third-party...
Search
- Mar 3
PuREC receives JETRO Kyoto Award at "3rd Kyoto Univesity Life Science Showcase @ San Diego 2022"
We are delighted to have been awarded with JETRO Kyoto Award at 3rd Kyoto University Life Science Showcase @ San Diego 2022. Event...
- Nov 30, 2021
Genesis 2021 Innovation Workshop at LINK-J session
We are happy to announce that PuREC is invited to Genesis 2021 Innovation Workshop speaker at LINK-J session. Genesis 2021 Innovation...
- Nov 8, 2021
Japan Healthcare Venture Summit (JHVS) global pitch
We are happy to announce that PuREC is selected one of the 8 finalists at the Japan Healthcare Venture Summit (JHVS) global pitch on 16...
- Oct 2, 2021
NEW: Clinical Trial using PuREC’s Rapid Expanding Cells for Hypophosphatase (HPP) Disease
A phase I/IIa clinical trial for hypophotase treatment has started in collaboration with Shimane University. This First in Human trial is...
- Oct 2, 2021
Joint research collaboration with Hokkaido University and Mochida Pharmaceutical
PuREC has started a joint research project with Hokkaido University and Mochida Pharmaceutical to developnew treatments for spinal...
- Oct 2, 2021
PuREC wins JHVS2020 Venture Award !
PuREC’s Morishita took the stage at "Japan Healthcare Venture Summit 2020" [October 14th to 16th] to present the company’s "90 seconds...